All Stories

  1. Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome
  2. Optimizing Placental Transfusion for Preterm Infants
  3. Serious Congenital Heart Disease and Necrotizing Enterocolitis in Very Low Birth Weight Neonates
  4. Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome
  5. Overview of ventilation strategies for the early management of intubated preterm infants
  6. Antibiotic Use in Neonatal Intensive Care
  7. Randomized Trial of Occlusive Wrap for Heat Loss Prevention in Preterm Infants
  8. Identifying improvements for delivery room resuscitation management: results from a multicenter safety audit
  9. Surfactant for meconium aspiration syndrome in term and late preterm infants
  10. Patterns of surgical practice in very low birth weight neonates born in the United States: a Vermont Oxford Network analysis
  11. The OPTIMIST-A trial: evaluation of minimally-invasive surfactant therapy in preterm infants 25–28 weeks gestation
  12. Timing of cord clamping in very preterm infants: more evidence is needed
  13. Probiotic Supplementation in Preterm Infants: It Is Time to Change Practice
  14. Clinical prediction models for bronchopulmonary dysplasia: a systematic review and external validation study
  15. Study protocol for multicentre randomized controlled trial of HeLP (Heat Loss Prevention) in the delivery room
  16. Calling Time on Intravenous Immunoglobulin for Preterm Infants?
  17. Lung lavage for meconium aspiration syndrome in newborn infants
  18. Cooling for Newborns with Hypoxic Ischemic Encephalopathy
  19. Early versus Delayed Selective Surfactant Treatment for Neonatal Respiratory Distress Syndrome
  20. Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants
  21. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome
  22. Initial Respiratory Support of Preterm Infants
  23. The Vermont oxford neonatal encephalopathy registry: rationale, methods, and initial results
  24. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants
  25. Inhaled Nitric Oxide for Respiratory Failure in Preterm Infants
  26. Early Erythropoietin for Preventing Red Blood Cell Transfusion in Preterm and/or Low Birth Weight Infants
  27. Prophylactic versus Selective Use of Surfactant in Preventing Morbidity and Mortality in Preterm Infants
  28. Neurodevelopmental Outcome of Infants Resuscitated with Air or 100% Oxygen: A Systematic Review and Meta-Analysis
  29. Diuretics for respiratory distress syndrome in preterm infants
  30. Hypothermia and Other Treatment Options for Neonatal Encephalopathy: An Executive Summary of the Eunice Kennedy Shriver NICHD Workshop
  31. Individual Patient Meta-analysis in Pediatrics
  32. Intratracheal instillation of corticosteroids using surfactant as a vehicle for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome
  33. Digoxin for preventing or treating neonatal respiratory distress syndrome
  34. Pharmacologic Adjuncts II
  35. Evidence-Based Delivery Room Care of the Very Low Birth Weight Infant
  36. Meta-analysis in Neonatal Perinatal Medicine
  37. Editors' Introduction
  38. The Cochrane Neonatal Review Group: who we are and what we have done
  39. Cochrane review: Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome
  40. Cochrane review: Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome
  41. Elective high-frequency oscillatory versus conventional ventilation in preterm infants: a systematic review and meta-analysis of individual patients' data
  42. Probiotics: Are We Ready for Routine Use?
  43. Feeding Practices and Patent Ductus Arteriosus Ligation Preferences—Are They Related?
  44. Evaluating the Medical Evidence for Quality Improvement
  45. The Vermont Oxford Network: A Community of Practice
  46. Prophylactic protein free synthetic surfactant for preventing morbidity and mortality in preterm infants
  47. Partial exchange transfusion to prevent neurodevelopmental disability in infants with polycythemia
  48. Prophylactic vitamin K for the prevention of vitamin K deficiency bleeding in preterm neonates
  49. Corticosteroids for the Treatment and Prevention of Bronchopulmonary Dysplasia
  50. Neurodevelopmental Outcome of Extremely Low Birth Weight Infants from the Vermont Oxford Network: 1998–2003
  51. Protein-containing synthetic surfactant versus protein-free synthetic surfactant for the prevention and treatment of respiratory distress syndrome
  52. Inhaled nitric oxide in the neonate
  53. Animal derived surfactant extract for treatment of respiratory distress syndrome
  54. Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome
  55. Current Trials in the Treatment of Respiratory Failure in Preterm Infants
  56. Heat loss prevention in neonates
  57. Diuretics for respiratory distress syndrome in preterm infants
  58. Updating reviews: the experience of the Cochrane Neonatal Review Group
  59. Resuscitation of Newborn Infants with 21% or 100% Oxygen: An Updated Systematic Review and Meta-Analysis
  60. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome
  61. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome
  62. Topical emollient therapy for preventing infection in preterm infants in low- or middle-income countries
  63. Surfactant for meconium aspiration syndrome in full term/near term infants
  64. Corticosteroids for the treatment and prevention of chronic lung disease
  65. Protein-containing synthetic surfactant versus protein-free synthetic surfactant for the prevention and treatment of respiratory distress syndrome
  66. Discussion 3: Focus on Ventilation
  67. Hypothermia and perinatal asphyxia: Executive summary of the National Institute of Child Health and Human Development workshop
  68. Ensuring Accurate Knowledge of Prematurity Outcomes for Prenatal Counseling: In Reply
  69. Overview of Surfactant Replacement Trials
  70. Partial exchange transfusion to prevent neurodevelopmental disability in infants with polycythemia
  71. New Synthetic Surfactants: The Next Generation?
  72. Neonatal polycythemia: is partial exchange transfusion justified?
  73. Choice and dose of corticosteroid for antenatal treatments
  74. High versus low thresholds for repeat administration of surfactant in intubated preterm neonates
  75. Cochrane neonatal systematic reviews: a survey of the evidence for neonatal therapies
  76. Metalloporphyrins for treatment of unconjugated hyperbilirubinemia in neonates
  77. PHARMACOLOGIC ADJUNCTS II
  78. CONTRIBUTORS
  79. Therapeutic lung lavage for meconium aspiration syndrome in newborn infants
  80. Lung Surfactants for Neonatal Respiratory Distress Syndrome
  81. Lung Surfactants for Neonatal Respiratory Distress Syndrome
  82. High vs low dose conventional phototherapy for neonatal jaundice
  83. CURRENT SURFACTANT USE IN PREMATURE INFANTS
  84. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants
  85. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome
  86. Superoxide dismutase for preventing chronic lung disease in mechanically ventilated preterm infants
  87. Patient-triggered ventilation of neonates
  88. Patient-triggered ventilation of the newborn
  89. Surfactant for meconium aspiration syndrome in full term infants
  90. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome
  91. Consensus and controversy over resuscitation of the ne wborn infant
  92. Multiple versus single dose natural surfactant extract for severe neonatal respiratory distress syndrome
  93. Early Postnatal Dexamethasone Therapy for the Prevention of Chronic Lung Disease
  94. Synthetic surfactant for respiratory distress syndrome in preterm infants
  95. Topical emollient for preventing infection in preterm infants
  96. Topical ointment for preventing infection in preterm infants
  97. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants
  98. Digoxin for preventing or treating neonatal respiratory distress syndrome
  99. Profile of Neonatal Follow-up Programs 1296
  100. Prophylactic Indomethacin to Prevent Intraventricular Hemorrhage: A Decision Analysis. † 1339
  101. Collaborative Quality Improvement for Neonatal Intensive Care. † 1026
  102. Surfactant Treatment of the Very Preterm Infant
  103. Introduction to Neonatal Systematic Reviews
  104. Prophylactic animal derived surfactant extract for preventing morbidity and mortality in preterm infants
  105. Role of extracorporeal membrane oxygenation
  106. Appropriate surfactant usage in 1996
  107. Neonatal extracorporeal membrane oxygenation—a bridging technique
  108. DETERMINATION OF SOMATIC MUTANT FREQUENCIES AT THE HPRT LOCUS IN T-LYMPHOCYTES FROM PRETERM INFANTS. † 394
  109. Artificial versus natural surfactant — Can we base clinical practice on a firm scientific footing?
  110. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome1
  111. Cost Effectiveness of Beractant in the Prevention of Respiratory Distress Syndrome
  112. Progress and problems in establishing an international registry of perinatal trials (IROPT)
  113. Radiographic Findings Associated with Surfactant Treatment
  114. Surfactant Replacement Therapy
  115. A Multicenter Randomized, Placebo-Controlled Trial of Surfactant Therapy for Respiratory Distress Syndrome
  116. Surfactant-associated Proteins in Tracheal Aspirates of Infants with Respiratory Distress Syndrome after Surfactant Therapy
  117. EVALUATION OF PULSE OXIMETER ACCURACY IN NEONATES
  118. Postoperative Care of the Newborn with Myelomeningocele